- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06833073
Un estudio clínico de V940 y BCG en personas con cáncer de vejiga (V940-011/Interpath-011)
Un estudio aleatorizado de fase 2 abierta de V940 en combinación con BCG versus monoterapia con BCG en participantes con cáncer de vejiga invasivo no muscular de alto riesgo (Interpath-011)
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder.
The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer.
The goal of this study is to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
As of Amendment 03 (effective 01/05/2026), outcome measures associated with the Intismeran autogene Monotherapy Arm (Cohort B) are no longer considered primary or secondary outcome measures.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Toll Free Number
- Número de teléfono: 1-888-577-8839
- Correo electrónico: Trialsites@msd.com
Ubicaciones de estudio
-
-
Baden-Wurttemberg
-
Stuttgart, Baden-Wurttemberg, Alemania, 70174
- Reclutamiento
- Klinikum Stuttgart - Katharinenhospital ( Site 0909)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4971127854720
-
-
Bavaria
-
Munich, Bavaria, Alemania, 81377
- Reclutamiento
- Klinikum der Universität München Großhadern ( Site 0910)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4989440072268
-
-
North Rhine-Westphalia
-
Herne, North Rhine-Westphalia, Alemania, 44625
- Reclutamiento
- Marienhospital Herne ( Site 0907)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4923234990
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Alemania, 06120
- Reclutamiento
- Universitaetsklinikum Halle ( Site 0902)
-
Contacto:
- Study Coordinator
- Número de teléfono: +49 345 557 5810
-
-
Thuringia
-
Jena, Thuringia, Alemania, 07747
- Reclutamiento
- Universitaetsklinikum Jena ( Site 0903)
-
Contacto:
- Study Coordinator
- Número de teléfono: +49 3641 9329901
-
-
-
-
-
La Rioja, Argentina, F5300COE
- Reclutamiento
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0301)
-
Contacto:
- Study Coordinator
- Número de teléfono: 543804425438
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1199ABD
- Reclutamiento
- Hospital Italiano de Buenos Aires ( Site 0307)
-
Contacto:
- Study Coordinator
- Número de teléfono: 541149590200
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
- Reclutamiento
- Instituto Alexander Fleming ( Site 0306)
-
Contacto:
- Study Coordinator
- Número de teléfono: 5491153288346
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Reclutamiento
- Instituto de Investigaciones Clinicas Mar de Plata ( Site 0305)
-
Contacto:
- Study Coordinator
- Número de teléfono: +542234963224
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1419AHN
- Reclutamiento
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 0303)
-
Contacto:
- Study Coordinator
- Número de teléfono: +541145740870
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DEJ
- Reclutamiento
- Fundacion Estudios Clinicos ( Site 0304)
-
Contacto:
- Study Coordinator
- Número de teléfono: +5403412221472
-
Rosario, Santa Fe Province, Argentina, S2000DSV
- Reclutamiento
- Sanatorio Parque ( Site 0300)
-
Contacto:
- Study Coordinator
- Número de teléfono: +543414268409
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australia, 2109
- Reclutamiento
- Macquarie University ( Site 1801)
-
Contacto:
- Study Coordinator
- Número de teléfono: +61298122968
-
-
Western Australia
-
Perth, Western Australia, Australia, 6150
- Reclutamiento
- Fiona Stanley Hospital ( Site 1803)
-
Contacto:
- Study Coordinator
- Número de teléfono: +61861511130
-
-
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80510-130
- Reclutamiento
- Instituto do Câncer e Transplante de Curitiba ( Site 0402)
-
Contacto:
- Study Coordinator
- Número de teléfono: +5541992057755
-
-
Rio Grande do Sul
-
Passo Fundo, Rio Grande do Sul, Brasil, 99010-260
- Reclutamiento
- Hospital de Clínicas de Passo Fundo ( Site 0406)
-
Contacto:
- Study Coordinator
- Número de teléfono: 55 54 981271411
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Reclutamiento
- Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0400)
-
Contacto:
- Study Coordinator
- Número de teléfono: +5517996782301
-
São Jose Do Rio Preto, São Paulo, Brasil, 15090-000
- Reclutamiento
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0410)
-
Contacto:
- Study Coordinator
- Número de teléfono: 551732015054
-
-
-
-
New Brunswick
-
Moncton, New Brunswick, Canadá, E1C 6Z8
- Reclutamiento
- The Moncton Hospital-Oncology ( Site 0200)
-
Contacto:
- Study Coordinator
- Número de teléfono: 5068574780
-
-
Quebec
-
Sherbrooke, Quebec, Canadá, J1H 5N4
- Reclutamiento
- Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0204)
-
Contacto:
- Study Coordinator
- Número de teléfono: 8193461110
-
-
-
-
-
Antofagasta, Chile, 1240000
- Reclutamiento
- Bradford Hill Norte ( Site 0503)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56442023631
-
-
Los Ríos Region
-
Valdivia, Los Ríos Region, Chile, 5112129
- Reclutamiento
- Oncocentro Valdivia ( Site 0507)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56958537020
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 8330032
- Reclutamiento
- Pontificia Universidad Catolica de Chile ( Site 0502)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56223543334
-
Santiago, Region M. de Santiago, Chile, 8420383
- Reclutamiento
- Bradfordhill ( Site 0501)
-
Contacto:
- Study Coordinator
- Número de teléfono: +562 29490970
-
Santiago, Region M. de Santiago, Chile, 7500921
- Reclutamiento
- Fundación Arturo López Pérez ( Site 0500)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56224218596
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Reclutamiento
- ONCOCENTRO APYS ( Site 0505)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56985719699
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050021
- Activo, no reclutando
- Promotora Médica Las Américas S.A. ( Site 0600)
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Colombia, 111321
- Reclutamiento
- Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0603)
-
Contacto:
- Study Coordinator
- Número de teléfono: +573016254437
-
-
Departamento de Córdoba
-
Montería, Departamento de Córdoba, Colombia, 230002
- Reclutamiento
- IMAT S.A.S ( Site 0601)
-
Contacto:
- Study Coordinator
- Número de teléfono: +576047862333
-
-
Risaralda Department
-
Pereira, Risaralda Department, Colombia, 661001
- Reclutamiento
- Oncólogos del Occidente S.A.S. - Sede Pereira ( Site 0604)
-
Contacto:
- Study Coordinator
- Número de teléfono: +573002558656
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia
- Reclutamiento
- Clínica Imbanaco S.A.S ( Site 0602)
-
Contacto:
- Study Coordinator
- Número de teléfono: +576023851000
-
-
-
-
Capital Region
-
Herlev, Capital Region, Dinamarca, 2730
- Reclutamiento
- Herlev and Gentofte Hospital ( Site 3101)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4538683868
-
-
-
-
-
Madrid, España, 28040
- Reclutamiento
- Hospital Clinico San Carlos... ( Site 1500)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34913303000
-
Madrid, España, 28041
- Reclutamiento
- Hospital Universitario 12 de Octubre ( Site 1507)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34913908121
-
Madrid, España, 28223
- Reclutamiento
- HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1506)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34914521987
-
Seville, España, 41009
- Reclutamiento
- Hospital Universitario Virgen Macarena ( Site 1504)
-
Contacto:
- Study Coordinator
- Número de teléfono: +3495500800
-
-
Barcelona
-
Sabadell, Barcelona, España, 08208
- Reclutamiento
- Hospital Universitari Parc Tauli ( Site 1505)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34937240084
-
-
Canary Islands
-
Las Palmas de Gran Canaria, Canary Islands, España, 35016
- Reclutamiento
- Hospital Insular de Gran Canaria ( Site 1502)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34928441738
-
-
-
-
California
-
Bakersfield, California, Estados Unidos, 93301
- Reclutamiento
- Michael G Oefelein Clinical Trials ( Site 0138)
-
Contacto:
- Study Coordinator
- Número de teléfono: 661-310-1063
-
Los Alamitos, California, Estados Unidos, 90720
- Activo, no reclutando
- Genesis Research, LLC ( Site 0141)
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- USC Norris Comprehensive Cancer Center ( Site 0123)
-
Contacto:
- Study Coordinator
- Número de teléfono: 800-872-2273
-
Torrance, California, Estados Unidos, 90503
- Reclutamiento
- Genesis Healthcare-Torrance ( Site 0140)
-
Contacto:
- Study Coordinator
- Número de teléfono: 310-542-0199
-
Torrance, California, Estados Unidos, 90505
- Reclutamiento
- Genesis Research LLC ( Site 0118)
-
Contacto:
- Study Coordinator
- Número de teléfono: 310-534-8400
-
-
Colorado
-
Littleton, Colorado, Estados Unidos, 80122
- Reclutamiento
- Urology Associates ( Site 0144)
-
Contacto:
- Study Coordinator
- Número de teléfono: 303-733-8848
-
-
Florida
-
Hialeah, Florida, Estados Unidos, 33016
- Reclutamiento
- Urological Research Network ( Site 0133)
-
Contacto:
- Study Coordinator
- Número de teléfono: 786-431-2014
-
-
Illinois
-
Chicago Ridge, Illinois, Estados Unidos, 60415
- Reclutamiento
- Associated Urological Specialists - Chicago Ridge ( Site 0139)
-
Contacto:
- Study Coordinator
- Número de teléfono: 708-566-6983
-
-
Louisiana
-
Lafayette, Louisiana, Estados Unidos, 70508
- Reclutamiento
- Southern Urology, LLC ( Site 0145)
-
Contacto:
- Study Coordinator
- Número de teléfono: 337-233-6665
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65212
- Reclutamiento
- University of Missouri Health Care ( Site 0126)
-
Contacto:
- Study Coordinator
- Número de teléfono: 573-882-7026
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68506
- Reclutamiento
- NHO Revive Research Institute, LLC ( Site 0137)
-
Contacto:
- Study Coordinator
- Número de teléfono: 402-484-4900
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111)
-
Contacto:
- Study Coordinator
- Número de teléfono: 646-960-1012
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45212
- Reclutamiento
- TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122)
-
Contacto:
- Study Coordinator
- Número de teléfono: 513-841-7700
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- OHSU Knight Cancer Institute - South Waterfront ( Site 0110)
-
Contacto:
- Study Coordinator
- Número de teléfono: 503-494-4779
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Estados Unidos, 19004
- Reclutamiento
- MidLantic Urology ( Site 0102)
-
Contacto:
- Study Coordinator
- Número de teléfono: 610-667-0458
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Reclutamiento
- The Conrad Pearson Clinic ( Site 0143)
-
Contacto:
- Study Coordinator
- Número de teléfono: 901-236-0957
-
-
Texas
-
Austin, Texas, Estados Unidos, 78759
- Reclutamiento
- Urology Austin, PLLC ( Site 0109)
-
Contacto:
- Study Coordinator
- Número de teléfono: 512-410-3773
-
Austin, Texas, Estados Unidos, 78705
- Reclutamiento
- Texas Oncology-Austin Central ( Site 0107)
-
Contacto:
- Study Coordinator
- Número de teléfono: 512-421-4235
-
-
Virginia
-
Virginia Beach, Virginia, Estados Unidos, 23462
- Reclutamiento
- Urology of Virginia ( Site 0125)
-
Contacto:
- Study Coordinator
- Número de teléfono: 757-457-5100
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- Reclutamiento
- University of Washington - Fred Hutchinson Cancer Center ( Site 0100)
-
Contacto:
- Study Coordinator
- Número de teléfono: 206-598-3300
-
-
-
-
Cote-d Or
-
Dijon, Cote-d Or, Francia, 21079
- Reclutamiento
- CHU Dijon Bourgogne ( Site 0802)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33380295753
-
-
Gironde
-
Bordeaux, Gironde, Francia, 33076
- Reclutamiento
- Bordeaux University Hospital - Pellegrin ( Site 0806)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33556795547
-
-
Haute-Normandie
-
Rouen, Haute-Normandie, Francia, 76031
- Reclutamiento
- CHU de Rouen- urology ( Site 0803)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33 2 32 88 89 90
-
-
Hauts-de-Seine
-
Suresnes, Hauts-de-Seine, Francia, 92150
- Reclutamiento
- Hôpital Foch-Urology department ( Site 0801)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33146252040
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Francia, 75010
- Reclutamiento
- Hôpital Saint-Louis ( Site 0807)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33142499620
-
-
-
-
-
Thessaloniki, Grecia, 570 01
- Reclutamiento
- European Interbalkan Medical Center-Oncology Department ( Site 1008)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0030 2310400213
-
-
Attica
-
Athens, Attica, Grecia, 155 62
- Reclutamiento
- Metropolitan General Hospital ( Site 1001)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0030 2106502831
-
Athens, Attica, Grecia, 115 26
- Reclutamiento
- Henry Dunant Hospital ( Site 1005)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0030 2106972246
-
Chaidari/Athens, Attica, Grecia, 124 62
- Reclutamiento
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1000)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0030 2105832549
-
-
-
-
-
Debrecen, Hungría, 4032
- Reclutamiento
- Debreceni Egyetem Klinikai Kozpont ( Site 1112)
-
Contacto:
- Study Coordinator
- Número de teléfono: +3652255256
-
-
Csongrád megye
-
Szeged, Csongrád megye, Hungría, 6725
- Reclutamiento
- Szegedi Tudomanyegyetem ( Site 1113)
-
Contacto:
- Study Coordinator
- Número de teléfono: +3662545404
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Hungría, 9024
- Reclutamiento
- Gyor- Moson- Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz ( Site 1116)
-
Contacto:
- Study Coordinator
- Número de teléfono: + 36 96 507 900
-
-
Heves County
-
Eger, Heves County, Hungría, 3300
- Reclutamiento
- Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet ( Site 1118)
-
Contacto:
- Study Coordinator
- Número de teléfono: +3636411444/3802
-
-
Szabolcs-Szatmár-Bereg
-
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungría, 4400
- Reclutamiento
- Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz Nyiregyhazi Josa Andras Tagkorhaza ( Site 1117)
-
Contacto:
- Study Coordinator
- Número de teléfono: +36 42 599 700
-
-
-
-
-
Arezzo, Italia, 52100
- Reclutamiento
- Azienda USL 8 di Arezzo ( Site 1203)
-
Contacto:
- Study Coordinator
- Número de teléfono: 00390575255434
-
Roma, Italia, 00168
- Reclutamiento
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1200)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0039 06 3015.7080
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Reclutamiento
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1202)
-
Contacto:
- Study Coordinator
- Número de teléfono: 003902.2390 4450
-
-
Roma
-
Rome, Roma, Italia, 00128
- Reclutamiento
- Istituto Nazionale Tumori Regina Elena ( Site 1201)
-
Contacto:
- Study Coordinator
- Número de teléfono: 003906 588961
-
-
-
-
Gelderland
-
Arnhem, Gelderland, Países Bajos, 6815 AD
- Reclutamiento
- Rijnstate ( Site 1307)
-
Contacto:
- Study Coordinator
- Número de teléfono: +31880058124
-
-
South Holland
-
Rotterdam, South Holland, Países Bajos, 3015 GD
- Reclutamiento
- Erasmus MC ( Site 1300)
-
Contacto:
- Study Coordinator
- Número de teléfono: +31 10 7041566
-
-
-
-
-
Lima, Perú, 15076
- Activo, no reclutando
- Hospital Militar Central Luis Arias Schereiber ( Site 0700)
-
-
Lima Province
-
Lima, Lima Province, Perú, 15036
- Reclutamiento
- Oncosalud ( Site 0701)
-
Contacto:
- Study Coordinator
- Número de teléfono: +515137900
-
-
Lima region
-
San Isidro, Lima region, Perú, 15038
- Activo, no reclutando
- IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0702)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polonia, 61-731
- Reclutamiento
- Clinical Research Center Spółka z ograniczoną odpowiedzialnością MEDIC-R Sp.k ( Site 1402)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48 500 799 053
-
-
Lesser Poland Voivodeship
-
Tarnów, Lesser Poland Voivodeship, Polonia, 33-100
- Reclutamiento
- Szpital Wojewódzki im. Świętego Lukasza SP ZOZ w Tarnowie ( Site 1404)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48146315000
-
Warszawa, Lesser Poland Voivodeship, Polonia, 02-781
- Terminado
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 1401)
-
-
-
-
-
Torquay, Reino Unido, TQ2 7AA
- Reclutamiento
- Torbay Hospital ( Site 1701)
-
Contacto:
- Study Coordinator
- Número de teléfono: +441803614567
-
-
Glasgow City
-
Glasgow, Glasgow City, Reino Unido, G12 0YN
- Reclutamiento
- Gartnavel General Hospital ( Site 1702)
-
Contacto:
- Study Coordinator
- Número de teléfono: +441413017000
-
-
London, City of
-
London, London, City of, Reino Unido, EC1A 7BE
- Reclutamiento
- St Bartholomew s Hospital ( Site 1700)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4402073777000
-
-
-
-
Bangkok
-
Dusit, Bangkok, Tailandia, 10300
- Reclutamiento
- Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 3002)
-
Contacto:
- Study Coordinator
- Número de teléfono: +6622443522
-
-
Changwat Khon Kaen
-
Muang, Changwat Khon Kaen, Tailandia, 40002
- Reclutamiento
- Faculty of Medicine - Khon Kaen University ( Site 3001)
-
Contacto:
- Study Coordinator
- Número de teléfono: +6643363746
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Is an individual whose most recent TURBT was performed within 12 weeks before randomization/allocation and showed BICR-confirmed high-risk NMIBC histology
Cohort A:
- Has high-risk non-muscle invasive (HG Ta, T1, and/or CIS) UC of the bladder
- Is BCG-naïve defined as either having never received BCG or having received BCG more than 2 years before high-risk NMIBC recurrence. Recurrence must be at least 24 months from the last exposure to BCG with evidence of complete response during the 2-year period post BCG
Cohort B:
- Has CIS +/-papillary non-muscle invasive UC of the bladder
- Is ineligible for, or refusing, any IVESIC therapy
- Is either BCG-naïve (as defined above) or BCG-exposed but did not receive protocol-specified minimum dosing of BCG and experienced recurrence of high-risk NMIBC within 2 years of the last dose of BCG
- Human immunodeficiency virus (HIV)-infected individuals must have well controlled HIV on antiretroviral therapy (ART)
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a history of or concurrent locally-advanced (ie, T2, T3, T4) or metastatic UC
- Has concurrent extravesical (ie, urethra, ureter, renal pelvis) non-muscle invasive UC or a history of extravesical non-muscle invasive UC that recurred within the last 2 years, with certain exceptions
- Has a known additional malignancy that is progressing or has required active treatment within the last 3 years
- Has had a myocardial infarction within 6 months of randomization/allocation
- Has received any systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation
- Has received prior treatment with a cancer vaccine
- Has immunodeficiency or is receiving chronic systemic steroid therapy
- Has active autoimmune disease that has required systemic treatment in the last 2 years
- Has any contraindication to IV contrast and gadolinium or is otherwise unable to have imaging with either computerized tomography urogram (CTU) or Magnetic resonance urography (MRU)
Cohort A:
- Has current active tuberculosis
- Has a known history of HIV infection
Cohort B:
- HIV-infected individuals with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intismeran autogene + BCG
Participants in Cohort A receive 1 mg of intismeran autogene via intramuscular (IM) injection every 3 weeks (Q3W) for 9 doses. Participants also receive 50 mg of TICE® BCG once weekly for 6 weeks, then once weekly on weeks 13-15, 25-27, 49-51, and 73-75. |
IM injection
Otros nombres:
Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.
Otros nombres:
|
|
Comparador activo: BCG
Participants in Cohort A receive 50 mg of TICE® BCG once weekly for 6 weeks, then once weekly on weeks 13-15, 25-27, 49-51, and 73-75 |
Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.
Otros nombres:
|
|
Experimental: Intismeran autogene
Participants in Cohort B receive 1 mg of intismeran autogene via intramuscular (IM) injection every 3 weeks (Q3W) for 9 doses. |
IM injection
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cohort A: Event-free Survival (EFS)
Periodo de tiempo: Up to approximately 5 years
|
EFS is defined as the time from randomization to any of the following events, as determined by blinded independent central review (BICR): High-grade (HG) non-invasive papillary carcinoma (Ta) or carcinoma in situ (CIS) in the bladder at the 24-week assessment or later; Any T1 stage disease in the bladder; Any T2 stage or greater in the bladder, including transurethral prostate stromal invasion of urothelial carcinoma (UC); High-risk disease (defined as HG Ta, CIS, ≥T1) of the urethra or upper tract (ureters, renal pelvis); Metastatic UC [defined as regional lymph node metastasis of UC (stage N1 or greater), or distant metastasis of UC including non-regional lymph nodes (stage M1)]; Or death due to any cause. The EFS for BCG-treated participants will be presented. |
Up to approximately 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cohort A: 12-Month Event-free Survival (EFS)
Periodo de tiempo: Up to approximately 12 months
|
EFS is defined as the time from randomization to any of the following events, as determined by BICR where applicable: HG Ta or CIS in the bladder at the 24-week assessment or later; Any T1 stage disease in the bladder; Any T2 stage or greater in the bladder, including transurethral prostate stromal invasion of UC; High-risk disease (defined as HG Ta, CIS, ≥T1) of the urethra or upper tract (ureters, renal pelvis); Metastatic UC [defined as regional lymph node metastasis of UC (stage N1 or greater), or distant lymph node or visceral metastasis of UC (stage M1)]; Or death due to any cause. The EFS at 12 months for BCG-treated participants will be presented. |
Up to approximately 12 months
|
|
Cohort A: 24-Month Event-free Survival (EFS)
Periodo de tiempo: Up to approximately 24 months
|
EFS is defined as the time from randomization to any of the following events, as determined by BICR where applicable: HG Ta or CIS in the bladder at the 24-week assessment or later; Any T1 stage disease in the bladder; Any T2 stage or greater in the bladder, including transurethral prostate stromal invasion of UC; High-risk disease (defined as HG Ta, CIS, ≥T1) of the urethra or upper tract (ureters, renal pelvis); Metastatic UC [defined as regional lymph node metastasis of UC (stage N1 or greater), or distant lymph node or visceral metastasis of UC (stage M1)]; Or death due to any cause. The EFS at 24 months for BCG-treated participants will be presented. |
Up to approximately 24 months
|
|
Cohort A: Recurrence-free Survival (RFS)
Periodo de tiempo: Up to approximately 5 years
|
RFS is defined as the time from randomization to any of the following events, as determined by BICR where applicable: HG Ta or CIS in the bladder at the 24-week assessment or later; Any T1 stage disease in the bladder; Any T2 stage or greater in the bladder, including transurethral prostate stromal invasion of UC; High-risk disease (defined as HG Ta, CIS, ≥T1) of the urethra or upper tract (ureters, renal pelvis); Metastatic UC [defined as regional lymph node metastasis of UC (stage N1 or greater), or distant lymph node or visceral metastasis of UC (stage M1)]; Death due to any cause; or any other UC recurrence including low-grade (LG) Ta at any timepoint as well as HG Ta or CIS in the bladder before the 24-week assessment. The RFS will be presented. |
Up to approximately 5 years
|
|
Cohort A: Disease-specific Survival (DSS)
Periodo de tiempo: Up to approximately 5 years
|
DSS is defined as the time from randomization to death due to bladder cancer. The DSS will be presented. |
Up to approximately 5 years
|
|
Cohort A: Overall Survival (OS)
Periodo de tiempo: Up to approximately 5 years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 5 years
|
|
Cohort A: 12 Month Overall Survival Rate (OSR)
Periodo de tiempo: Up to approximately 12 months
|
OSR is defined as the percentage of participants who are alive at 12 months. The 12 month OSR for BCG-treated participants will be presented. |
Up to approximately 12 months
|
|
Cohort A: 24 Month Overall Survival Rate (OSR)
Periodo de tiempo: Up to approximately 24 months
|
OSR is defined as the percentage of participants who are alive at 24 months. The 24 month OSR for BCG-treated participants will be presented. |
Up to approximately 24 months
|
|
Cohort A: Complete Response Rate (CRR)
Periodo de tiempo: Up to approximately 5 years
|
CRR is defined as the percentage of participants who achieve a Complete Response (CR) defined as the absence of all of the following as determined by BICR: High-risk non-muscle invasive UC (defined as HG Ta, CIS, or any T1 disease of the bladder, urethra, or upper tract [ureters, renal pelvis]); Any T2 or greater in the bladder, including transurethral prostate stromal invasion of UC; Metastatic UC [defined as regional lymph node metastasis of UC (N1 or greater), or distant metastasis of UC including non-regional lymph nodes (M1)]. The CRR for BCG-treated participants will be presented. |
Up to approximately 5 years
|
|
Cohort A: Duration of Response (DOR)
Periodo de tiempo: Up to approximately 5 years
|
For participants who achieve a Complete Response (CR: the absence of all of the following as determined by BICR using urine cytology, biopsy, and radiology assessments as applicable, and local cystoscopy evaluation: High-risk non-muscle invasive UC (defined as HG Ta, CIS, or any T1 UC in the bladder, urethra; Any T2 or greater UC in the bladder, including transurethral prostate stromal invasion of UC; Extravesical UC as defined in CR; Metastatic UC [defined as regional lymph node metastasis of UC (N1 or greater), or distant lymph node or visceral metastasis of UC (M1)]), DOR is defined as the time from first documented CR to the first occurrence of any of the following: High-risk non-muscle invasive UC; muscle-invasive bladder cancer (MIBC) or locally-advanced or metastatic UC; Or death due to any cause. DOR as assessed by BICR will be presented. |
Up to approximately 5 years
|
|
Cohort A: Time to Cystectomy
Periodo de tiempo: Up to approximately 5 years
|
Time to cystectomy, defined as the time from randomization to the date of radical cystectomy, will be presented for BCG-treated participants. |
Up to approximately 5 years
|
|
Cohort A: Number of Participants Who Experience an Adverse Event (AE)
Periodo de tiempo: Up to approximately 21 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE in the study will be presented. |
Up to approximately 21 months
|
|
Cohort A: Number of Participants Who Discontinue Study Intervention Due to an AE
Periodo de tiempo: Up to approximately 18 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue the study intervention due to an AE in the study will be presented. |
Up to approximately 18 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Medical Director, Merck Sharp & Dohme LLC
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Neoplasias Urológicas
- Carcinoma
- Enfermedades de la vejiga urinaria
- Neoplasias vesicales sin invasión muscular
- Carcinoma in situ
- Neoplasias de la vejiga urinaria
- Productos biológicos
- Mezclas complejas
- Vacunas bacterianas
- Vacunas
- Vacunas de tuberculosis
- Vacuna BCG
Otros números de identificación del estudio
- V940-011
- V940-011 (Otro identificador: MSD)
- 2024-517335-46-00 (Identificador de registro: EU CT)
- U1111-1312-0572 (Identificador de registro: UTN)
- INTerpath-011 (Otro identificador: MSD)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .